Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome

Thomas P. Greco, Ann Marie Conti-Kelly, Thomas Greco, Robin Doyle, Eiji Matsuura, J. Robert Anthony, Luis R. Lopez

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Antiphospholipid antibodies (aPLs) have been implicated in atherogenesis. We studied 344 patients with acute coronary syndromes; approximately 40% were aPL+ in 1 or more tests and 60% aPL-. In 215 patients, coronary artery disease (CAD) was angiographically documented, with 43.7% positive for aPL vs 34.9% of patients without CAD positive for aPLs. Anti-β2-glycoprotein I (β2GPI; 54%) and antioxidized low-density lipoprotein (oxLDL)/β2GPI (48%) were most frequent, accounting for 87% of all aPL+ CAD cases. aPLs correlated with severity of CAD (P = .012). Adverse events occurred in 16.7% of patients with CAD, more frequently in patients who were aPL+ (P = .0006; relative risk, 2.9; 95% confidence interval, 1.5-5.6). Patients who were aPL+ with severe CAD had more adverse events than patients who were aPL- with severe CAD (P = .005) and aPL+ patients undergoing revascularization procedures (P = .001). Vascular events occurred in 21.7% of aPL+ patients compared with 7.1% of aPL- patients (P = .005). Anti-β2GPI and anti-oxLDL/β2GPI were associated with CAD severity and adverse outcomes.

Original languageEnglish
Pages (from-to)613-620
Number of pages8
JournalAmerican Journal of Clinical Pathology
Volume132
Issue number4
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Antiphospholipid Antibodies
Acute Coronary Syndrome
Coronary Artery Disease
LDL Lipoproteins
Blood Vessels
Atherosclerosis
Glycoproteins
Confidence Intervals

Keywords

  • Anti-β-glycoprotein i
  • Antiphospholipid antibodies
  • Coronary artery disease
  • Oxidized low-density lipoprotein

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome. / Greco, Thomas P.; Conti-Kelly, Ann Marie; Greco, Thomas; Doyle, Robin; Matsuura, Eiji; Anthony, J. Robert; Lopez, Luis R.

In: American Journal of Clinical Pathology, Vol. 132, No. 4, 10.2009, p. 613-620.

Research output: Contribution to journalArticle

Greco, Thomas P. ; Conti-Kelly, Ann Marie ; Greco, Thomas ; Doyle, Robin ; Matsuura, Eiji ; Anthony, J. Robert ; Lopez, Luis R. / Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome. In: American Journal of Clinical Pathology. 2009 ; Vol. 132, No. 4. pp. 613-620.
@article{0bb9bec87b4f4e2ab4dd1caecf0618e9,
title = "Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome",
abstract = "Antiphospholipid antibodies (aPLs) have been implicated in atherogenesis. We studied 344 patients with acute coronary syndromes; approximately 40{\%} were aPL+ in 1 or more tests and 60{\%} aPL-. In 215 patients, coronary artery disease (CAD) was angiographically documented, with 43.7{\%} positive for aPL vs 34.9{\%} of patients without CAD positive for aPLs. Anti-β2-glycoprotein I (β2GPI; 54{\%}) and antioxidized low-density lipoprotein (oxLDL)/β2GPI (48{\%}) were most frequent, accounting for 87{\%} of all aPL+ CAD cases. aPLs correlated with severity of CAD (P = .012). Adverse events occurred in 16.7{\%} of patients with CAD, more frequently in patients who were aPL+ (P = .0006; relative risk, 2.9; 95{\%} confidence interval, 1.5-5.6). Patients who were aPL+ with severe CAD had more adverse events than patients who were aPL- with severe CAD (P = .005) and aPL+ patients undergoing revascularization procedures (P = .001). Vascular events occurred in 21.7{\%} of aPL+ patients compared with 7.1{\%} of aPL- patients (P = .005). Anti-β2GPI and anti-oxLDL/β2GPI were associated with CAD severity and adverse outcomes.",
keywords = "Anti-β-glycoprotein i, Antiphospholipid antibodies, Coronary artery disease, Oxidized low-density lipoprotein",
author = "Greco, {Thomas P.} and Conti-Kelly, {Ann Marie} and Thomas Greco and Robin Doyle and Eiji Matsuura and Anthony, {J. Robert} and Lopez, {Luis R.}",
year = "2009",
month = "10",
doi = "10.1309/AJCP2FJUT2YZGITK",
language = "English",
volume = "132",
pages = "613--620",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "4",

}

TY - JOUR

T1 - Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome

AU - Greco, Thomas P.

AU - Conti-Kelly, Ann Marie

AU - Greco, Thomas

AU - Doyle, Robin

AU - Matsuura, Eiji

AU - Anthony, J. Robert

AU - Lopez, Luis R.

PY - 2009/10

Y1 - 2009/10

N2 - Antiphospholipid antibodies (aPLs) have been implicated in atherogenesis. We studied 344 patients with acute coronary syndromes; approximately 40% were aPL+ in 1 or more tests and 60% aPL-. In 215 patients, coronary artery disease (CAD) was angiographically documented, with 43.7% positive for aPL vs 34.9% of patients without CAD positive for aPLs. Anti-β2-glycoprotein I (β2GPI; 54%) and antioxidized low-density lipoprotein (oxLDL)/β2GPI (48%) were most frequent, accounting for 87% of all aPL+ CAD cases. aPLs correlated with severity of CAD (P = .012). Adverse events occurred in 16.7% of patients with CAD, more frequently in patients who were aPL+ (P = .0006; relative risk, 2.9; 95% confidence interval, 1.5-5.6). Patients who were aPL+ with severe CAD had more adverse events than patients who were aPL- with severe CAD (P = .005) and aPL+ patients undergoing revascularization procedures (P = .001). Vascular events occurred in 21.7% of aPL+ patients compared with 7.1% of aPL- patients (P = .005). Anti-β2GPI and anti-oxLDL/β2GPI were associated with CAD severity and adverse outcomes.

AB - Antiphospholipid antibodies (aPLs) have been implicated in atherogenesis. We studied 344 patients with acute coronary syndromes; approximately 40% were aPL+ in 1 or more tests and 60% aPL-. In 215 patients, coronary artery disease (CAD) was angiographically documented, with 43.7% positive for aPL vs 34.9% of patients without CAD positive for aPLs. Anti-β2-glycoprotein I (β2GPI; 54%) and antioxidized low-density lipoprotein (oxLDL)/β2GPI (48%) were most frequent, accounting for 87% of all aPL+ CAD cases. aPLs correlated with severity of CAD (P = .012). Adverse events occurred in 16.7% of patients with CAD, more frequently in patients who were aPL+ (P = .0006; relative risk, 2.9; 95% confidence interval, 1.5-5.6). Patients who were aPL+ with severe CAD had more adverse events than patients who were aPL- with severe CAD (P = .005) and aPL+ patients undergoing revascularization procedures (P = .001). Vascular events occurred in 21.7% of aPL+ patients compared with 7.1% of aPL- patients (P = .005). Anti-β2GPI and anti-oxLDL/β2GPI were associated with CAD severity and adverse outcomes.

KW - Anti-β-glycoprotein i

KW - Antiphospholipid antibodies

KW - Coronary artery disease

KW - Oxidized low-density lipoprotein

UR - http://www.scopus.com/inward/record.url?scp=70349582320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349582320&partnerID=8YFLogxK

U2 - 10.1309/AJCP2FJUT2YZGITK

DO - 10.1309/AJCP2FJUT2YZGITK

M3 - Article

C2 - 19762540

AN - SCOPUS:70349582320

VL - 132

SP - 613

EP - 620

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 4

ER -